

Department of Pharmaceuticals

1. National Institutes of Pharmaceutical Education and Research (NIPERs) (CS)

Financial Outlay (Rs. in cr.)	Outputs 2024-25			Outcome 2024-25				
	FY 2024-25	Output	Indicator	Target 2024-25	Outcome	Indicator	Targets 2024-25	
242.00	1.	Construction of regular campus for NIPERs- Hyderabad, Raebareli, and Kolkata	1.1. Construction of regular campus (% of progress) (Hyderabad)	50	1.	NIPERs with their own building and campus	1.1. NIPERs functional from their own campus	4
			1.2. Construction of regular campus (% of progress) (Raebareli)	100				
			1.3. Construction of regular campus (% of progress) (Kolkata)	50				
	2.	Number of students trained in pharmaceutical education for industry	1.1. Intake of students for Masters level Courses in NIPERs (in numbers)	1,000	2.	Increase in number of experts & professionals for the industry	2.1. Percentage of students getting placements	90
			1.2. No. of short-term technical courses completed at NIPERs	50	3.	Research publications & Patents	3.1 No. of research papers published in high impact journals	250
			1.3. Number of students who completed PhD course from NIPERs	50			3.2 No. of patents filed through research at NIPERs	25

## 2. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) (CS)

Financial Outlay (Rs. in Cr.) 2024-25	Outputs 2024-25			Outcome 2024-25		
	Output	Indicator(s)	Targets 2024-25	Outcome	Indicator(s)	Targets 2024-25
284.50	1. Operationalize Jan Aushadhi Kendras in the country	1.1. Number of new Janaushadhi Kendras setup in the country	5,000	1. Enhanced coverage	1.1. Percentage of districts covered in India	100
	2. Enhanced sales turnover of medicines under PMBJP	2.1 Annual increase in sales turnover of medicines (in Rs. crore)	400	2. Reduction of out-of-pocket expenditure on medicines	2.1 Estimated savings to consumers (in Rs. Crore)	2,000
	3. Ensure stocking mandate for commonly used medicines	3.1 No. of medicines under Min. Stocking Mandate at Jan Aushadhi Kendras	200	3. Increase in availability of medicines at PMBJKs	3.1 PMBJK stores where Min. stocking mandate is to be achieved (in %)	60

## 3. Consumer Awareness, Publicity and Price Monitoring (CAPPM) (CS)

Financial Outlay (Rs. in Cr.) 2024-25	Outputs 2024-25			Outcome 2024-25		
	Output	Indicator(s)	Targets 2024-25	Outcome	Indicator(s)	Targets 2024-25
4.00	1. Awareness creation through publicity and advertisement	1.1. Number of Publicity Campaign through Hoardings, LED Screens, social media etc.	2	1. Improving knowledge and awareness about availability of	1.1. Average number of unique views per Digital campaign	500
		1.2. Number of Seminars/ Webinar/ Workshops/ Conferences organized	2		1.2. No. of individuals/ stakeholders participating	500

Financial Outlay (Rs. in Cr.) 2024-25	Outputs 2024-25			Outcome 2024-25		
	Output	Indicator(s)	Targets 2024-25	Outcome	Indicator(s)	Targets 2024-25
				medicines, ceiling prices of medicines fixed by the Govt., precautions to be taken while purchasing medicines and about functioning of NPPA	in Seminars/ Webinars/ Conferences organized	
				2. Monitoring prices of drugs, pursue overcharge cases, address shortages and generate public awareness about affordable drugs.	2.1. Percentage of complaints acted upon / addressed by NPPA for violation of pricing mechanism	100

**4. Scheme for Promotion of Research and Innovation in Pharma-Med Tech (PRIP) (CS)**

Financial Outlay (Rs. In Cr. 2024-25)	Output 2024-25			Outcome 2024-25		
	Output	Indicator	Target 2024-25	Outcome	Indicator	Target 2024-25
75.00	1. Setting up of CoE under component A	1.1. Proposals of respective NIPERs for setting up the CoE (in nos)	7	1. Component -A -Strengthening the R&D infrastructure and activities at NIPERs.	1.1. Approval of CoE in NIPER (in nos)	7
	2. Selection of Companies/Start-ups under Component-B	2.1. Selection of eligible companies under Component B (in nos)	20	2. Component -B Promotion of private initiative in R&D in Pharma Meditech sector in six priority areas.	2.2. Release of the first tranche of funds to the selected companies under Component B.	20